March 01, 2021
Artizan Biosciences Closes $11 Million Series A-2 Financing and Enters Option and License Agreement with Biohaven Therapeutics
Agreement enables Biohaven to exercise option on up to three of Artizan’s candidates for the treatment of inflammatory bowel disease. Series A-2 led by Hatteras Venture Partners and Biohaven. Donnie McGrath, M.D., and Seth Rudnick, M.D., join Artizan’s board of directors.
June 10, 2019
Finalized Series A funding, bringing total raised to date to $12MM to support proprietary platform that enables identification of disease-driving bacteria and development of therapies for inflammatory diseases. Appointed Paul Miller, PhD, as Chief Scientific Officer. Moved to specialized microbiology facility in New Haven’s Science Park.